Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Breast Neoplasms

Rectal Neoplasms

Gastric Adenocarcinoma

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

HER2-low Breast Cancer

Breast Neoplasms

Stomach Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Advanced Breast Cancer

Breast Neoplasms

Stomach Neoplasms

Breast Neoplasms

Biliary Tract Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Urinary Bladder Neoplasms

Uterine Cervical Neoplasms

Breast Neoplasms

HER2-positive Gastric Cancer

Stomach Neoplasms

Lung Neoplasms

Prostatic Neoplasms

Ovarian Cancer Recurrent

Metastatic HER2 Positive Gastroesophageal Junction Cancer

Breast Neoplasms

Stomach Neoplasms

Non-Muscle Invasive Bladder Neoplasms

High-risk Non-muscle Invasive Bladder Cancer

HER2-positive Gastric Cancer

Castration-resistant Prostate Cancer

Breast Neoplasms

Stomach Neoplasms

Pancreatic Neoplasms

Stomach Neoplasms

Uterine Cervical Neoplasms

HER2-positive Metastatic Breast Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Transitional Cell

Stomach Neoplasms

Colorectal Neoplasms

Stomach Neoplasms

Muscle Invasive Bladder Carcinoma

Non-Muscle Invasive Bladder Neoplasms

Muscle Invasive Bladder Cancer

Clinical Trials

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

DTP-HER2

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

BRIGHT

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

RC48-ADC in HER2-low Advanced Breast Cancer

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Disitamab Vedotin (RC48-ADC) in Breast Cancer

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

DECIDING

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

DAB

DIVON

Neoadjuvant Therapy in Cervical Cancer

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

RCTS

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

DETECT

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC